Inflammaging and Midlife Women: Translating Geroscience into Clinical Practice

Dr. Atul Munshi Editor-in-Chief

Dr. Ruchika Garg Editor-in-Chief

Aging is no longer viewed merely as the passive passage of time. Instead, it is increasingly understood as an active biological process driven by complex interactions between immunity, metabolism, hormones, and environment. One of the most compelling concepts to emerge from this paradigm shift is “inflammaging” – a state of chronic, low-grade inflammation that accompanies aging and underlies many age-related diseases. Coined by Claudio Franceschi over two decades ago, inflammaging has now become a cornerstone of geroscience, linking immune dysregulation with longevity and disease vulnerability.[1]

For women, midlife and menopause represent a critical biological modulation point in the inflammaging trajectory. The menopausal transition is not simply a reproductive milestone; it is a systemic event with far-reaching immunological, metabolic, cardiovascular, skeletal, and neurocognitive implications.[2] As life expectancy for Indian women has risen dramatically – from approximately 35 years before independence to over 70 years today – the relevance of inflammaging in midlife women has never been greater. This editorial argues that adopting the inflammaging framework moves us beyond treating menopausal symptoms in isolation and toward a unified strategy for preventing the chronic diseases of aging.

INFLAMMAGING MATTERS IN MIDLIFE

The risk of health problems from all causes increases rapidly after the age of 50 years, doubling approximately every 8 years. This acceleration coincides with immunosenescence – a gradual decline in immune competence – paradoxically accompanied by heightened inflammatory signaling. Elevated circulating levels of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP) are consistently associated with frailty, sarcopenia, insulin resistance, atherosclerosis, osteoporosis, cognitive decline, and malignancy.

In women, the menopausal decline in estrogen acts as a powerful biological amplifier of this inflammatory milieu. Estrogen is not merely a reproductive hormone; it is a key immunomodulator with anti-inflammatory, antioxidant, and mitochondrial-protective actions. Its withdrawal unmasks inflammatory pathways that were previously restrained, accelerating biological aging.

Menopause acts as an accelerator of inflammaging. The loss of 17β-estradiol during menopause leads to disinhibition of nuclear factor-κB signaling, resulting in increased transcription of inflammatory cytokines. Simultaneously, estrogen deficiency contributes to mitochondrial dysfunction, increased reactive oxygen species generation, and cellular senescence.[3,4] Senescent cells accumulate in aging tissues and secrete a pro-inflammatory senescence-associated secretory phenotype, perpetuating local and systemic inflammation.[5]

Clinically, this biology manifests as increased visceral adiposity, insulin resistance, dyslipidemia, endothelial dysfunction, bone loss, and neuroinflammation – hallmarks of postmenopausal morbidity. Importantly, inflammaging provides a unifying mechanism linking menopause to chronic diseases traditionally considered unrelated.[6] The key mechanistic pathways underlying this process are summarized in Table 1.

Table 1.

Menopause as an accelerator of inflammaging: Pathophysiological trigger[6]

Mechanistic axis	Integrated pathway and clinical translation
Estrogen withdrawal	Loss of 17β-estradiol removes inhibition of NF-κB signaling → ↑ IL-6, TNF-α, IL-1β → chronic low-grade systemic inflammation and rising cardiometabolic vulnerability
Mitochondrial dysfunction	Impaired oxidative phosphorylation → ↑ reactive oxygen species → oxidative stress and endothelial dysfunction → accelerated vascular aging
Decline in antioxidant defense	Reduced antioxidant enzyme regulation → cumulative oxidative damage → premature tissue and vascular aging
Cellular senescence	DNA damage response and telomere attrition → accumulation of senescent cells → tissue dysfunction, frailty, and loss of resilience
SASP amplification	Senescent cells secrete IL-6, IL-8, MCP-1, MMPs, growth factors → local and systemic inflammatory amplification → cardiometabolic, musculoskeletal, and neurocognitive risk
Immune dysregulation	Altered innate and adaptive immunity (macrophage activation, T-cell senescence) → persistent sterile inflammation (“inflammaging”) → increased multimorbidity in postmenopausal women

↑: Increased. IL: Interleukin, TNF- α: Tumor necrosis factor-alpha, SASP: Senescence-associated secretory phenotype, MCP-1: Monocyte chemotactic protein-1, MMPs: Matrix metalloproteinases

There are gender differences in immune aging. Sex-based differences in immune aging are increasingly recognized. Women generally mount stronger immune responses than men during reproductive years, conferring advantages in infection control but also higher susceptibility to autoimmune diseases. After menopause, however, the abrupt decline in estrogen leads to a steeper rise in inflammatory biomarkers compared to the more gradual inflammaging observed in aging men with declining testosterone levels.

These differences have implications for disease patterns, vaccine responses, and therapeutic strategies. Understanding inflammaging through a gender-sensitive lens is therefore essential for precision midlife medicine.

In India, this may be viewed as “A Silent Epidemic.” India faces a unique convergence of challenges. Rapid urbanization, dietary transitions, physical inactivity, psychosocial stress, and increasing obesity have created a fertile ground for chronic low-grade inflammation – even before menopause. High-glycemic diets, trans fats, excess refined carbohydrates, and sugary beverages contribute to insulin spikes and adipose-driven cytokine release, fuelling inflammaging at younger ages.

For Indian women, who often prioritize family health over their own and may have limited access to preventive care, menopause frequently coincides with undiagnosed cardiometabolic risk. Inflammaging thus becomes a silent epidemic – clinically invisible until overt disease emerges.

An important question is whether inflammaging can be modified? Emerging evidence suggests that aspects of inflammaging may be modifiable. Unlike chronological aging, biological aging is responsive to targeted interventions – many of which are accessible, cost-effective, and culturally adaptable.

It is crucial to note that the anti-inflammatory benefits of menopausal hormone therapy (MHT) are most pronounced when initiated during the perimenopause or early postmenopause – the “window of opportunity” – before atherogenesis and inflammatory pathways are fully established. Late initiation may not reverse established inflammaging and could potentially trigger adverse events. MHT, when initiated within the “window of opportunity,” has been shown to modulate the inflammatory markers such as IL-6, TNF-α, and CRP, improve lipid profiles, and enhance vascular function. Beyond symptom relief, MHT may favorably influence immune aging in appropriately selected women.[7]

Lifestyle interventions play an important role in reducing inflammatory response. Regular physical activity – combining aerobic exercise with resistance training – reduces visceral fat, enhances anti-inflammatory cytokines like IL-10, and improves mitochondrial efficiency. Adequate sleep, stress reduction, smoking cessation, and moderation of alcohol intake are foundational pillars in reducing inflammatory burden.

Mind–body perspectives such as yoga, pranayama, and mindfulness meditation have demonstrated reductions in CRP and IL-6 and favorable modulation of the hypothalamic–pituitary–adrenal axis. These practices, deeply rooted in Indian tradition, align seamlessly with modern concepts of stress biology and immune regulation. The potential pathways through which these interventions may modify inflammaging are illustrated in Figure 1.[8]

Figure 1.

Can Inflammaging Be Modified?[8] MHT: Menopausal hormone therapy

Nutrition and the gut–immune axis include plant-rich diets, omega-3 fatty acids, polyphenols, antioxidants, and adequate dietary fiber support a healthy gut microbiome, a key regulator of systemic inflammation. The gut–immune–brain axis is increasingly recognized as a central player in inflammaging, particularly in midlife women. Gut dysbiosis may increase inflammatory reactions.

Beyond lifestyle and hormones, several pharmacologic agents and emerging therapies are being investigated for their anti-inflammaging potential. Metformin, statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers demonstrate pleiotropic anti-inflammatory effects. Senolytics, mTOR inhibitors such as rapamycin, NAD⁺ boosters, and selective estrogen receptor modulators represent the frontier of geroprotective medicine.[9]

Ayurvedic concepts of “Rasayana” – aimed at rejuvenation and tissue resilience – offer a complementary framework. Adaptogens such as Ashwagandha and Shilajit have shown antioxidant and anti-inflammatory effects in emerging clinical studies. While rigorous evidence is still evolving, these approaches merit scientific exploration rather than dismissal.[10]

However, enthusiasm must be tempered with caution. Most of these interventions remain investigational for aging per se, and their role in midlife women requires robust, long-term data. Indian women experience menopause at a mean age of approximately 46–48 years, nearly 4–5 years earlier than Western counterparts, potentially extending the duration of estrogen-deficient exposure.

“At present, routine inflammatory marker screening is not recommended solely to assess menopausal status. However, high-sensitivity CRP may aid cardiovascular risk stratification in selected women.”

In conclusion, inflammation should be regarded as a key contributor to menopausal morbidity rather than merely an incidental laboratory finding. Screening strategies that include obesity, metabolic parameters, and selective inflammatory markers can help identify high-risk women who may benefit from aggressive risk factor modification. Furthermore, there is an urgent need for Indian cohort studies to track inflammaging biomarkers in our unique population, considering our genetic admixture, dietary patterns, and high rates of metabolic syndrome. These data are essential for developing personalized, cost-effective interventions.

Inflammaging reframes menopause from an isolated endocrine event to a systemic, immune-metabolic transition with broad implications for long-term health. Inflammaging is not an inevitable fate of aging but a modifiable biological process. For the midlife woman, it represents not just a new dimension of risk but also our clearest opportunity yet for intervention.